Medical Device Single Audit Program (MDSAP)

Medical Device Single Audit Program

Medical Device Single Audit Program (MDSAP) allows a single audit of a medical device manufacturer's QMS which satisfies the requirements of multiple regulatory jurisdictions. Audits are conducted by Auditing Organizations (AO), such as BSI, authorized by the participating Regulatory Authorities (RA) to audit under MDSAP requirements.

MDSAP is a way that medical device manufacturers can be audited once for compliance with the standard and regulatory requirements of up to five different medical device markets: Australia, Brazil, Canada, Japan and the United States.

A BSI MDSAP Audit can also be combined with assessment for CE and ISO 13485.

MDSAP audits can be performed by a recognized MDSAP Auditing Organisations (AO), such as BSI. BSI have been active through the MDSAP pilot phase and have now received significant numbers of applications for MDSAP, predominantly from world leading medical device manufacturers. BSI has performed over 200 MDSAP audits worldwide and issued a significant number of global sites with MDSAP certifications and we are currently processing many more.

FDA guidance on MDSAP can be accessed below:

MDSAP Guidance Documents

Access full details of the MDSAP pilot

View a comprehensive explanatory webinar

Which Regulatory Authorities are part of the initiative?

MDSAP should be considered for companies based globally, if they wish to export products into the countries participating, as described below.

The five RA’s involved with MDSAP have made the following statements on how they intend to utilize MDSAP reports:

  • Australia: The Therapeutics Goods Administration TGA uses an MDSAP audit report as part of the evidence that is assessed for compliance with medical device market authorization requirements, unless the medical device is otherwise excluded or exempt from these requirements or if current policies restrict the use of MDSAP audit reports.
  • Brazil: The Brazilian National Health Surveillance Agency ANVISA utilizes the outcomes of the program, including the reports, to constitute an important input on ANVISA’s pre-market and post-market assessment procedures. Providing, when applicable, key information that are expected to support regulatory technical evaluation on these issues.
  • Canada: Health Canada HC have confirmed the requirement for medical device manufacturers to transition from CMDCAS to MDSAP to continue to place devices into Canada. From 1 January 2019 Health Canada will ONLY accept MDSAP for manufacturers who market their devices in Canada. Therefore, manufacturers wishing to continue to place product on the market in Canada as of 2019, need to have MDSAP Certification issued by an AO inplace before that date.
  • United States: U.S. Food and Drug Administration’s Center for Devices and Radiological Health FDA will accept the MDSAP audit reports as a substitute for FDA routine inspections. Inspections conducted "For Cause" or "Compliance Follow-up" by FDA will not be affected by this program. Moreover, this MDSAP program would not apply to any necessary pre-approval or post approval inspections for Premarket Approval (PMA) applications or to decisions under section 513(f)(5) of the Act (21 U.S.C. 360c(f)(5)) concerning the classification of a device.
  • Japan: The Ministry of Health, Labour and Welfare (MHLW) and Pharmaceutical and Medical Devices Agency (PMDA) will utilize these audit reports in both premarket and periodical post market audit under regulations in Japan.